# Autoscreen: An innovative e-health solution for early identification of Autism Spectrum Disorder Phase II

> **NIH NIH R44** · ADAPTIVE TECHNOLOGY CONSULTING, LLC · 2020 · $484,987

## Abstract

PROJECT SUMMARY
Early accurate identification and treatment of young children with Autism Spectrum Disorder (ASD) represents
a pressing public health and clinical care challenge. Given mounting evidence that early, accurate diagnosis of
ASD is possible and that very young children who receive intervention can demonstrate substantial gains in
functioning, current American Academy of Pediatrics practice guidelines endorse formal ASD screening at 18
and 24 months of age. Ideally, this recommended screening would translate into early diagnosis and treatment
for most children. Unfortunately, large numbers of children are still not screened for ASD; waits for specialized
diagnostic assessment can be very long; and the average age of diagnosis in the US remains between 4 to 5
years of age. Furthermore, groups from traditionally underserved communities are even more likely to be
diagnosed at later ages. Delays in accurate diagnosis contribute to high levels of family stress and limit access
to ASD behavioral intervention services, which are increasingly recognized as very important to children’s
functioning. Continuing work initiated in our Phase I project, the current project rigorously tests “Autoscreen”—a
digital tool for rapid screening, diagnostic triage, referral, and treatment engagement of young children within
community pediatric settings, with an embedded focus on reaching underserved populations. This tool fuses
advanced computational strategies with expert knowledge and tools for ASD screening/assessment in order to
realize a commercial tool that not only provides support for enhanced, reimbursable screening across diverse
communities, but also establishes a clear decision pathway for early, accurate diagnostic triage and meaningful
engagement in early treatment. In Phase II, we will rigorously evaluate the validity and broader clinical utility of
Autoscreen. If successful, this innovative product could identify and link children with ASD to meaningful
interventions at younger ages. We believe that a substantial potential market for such a system exists, given that
commonly used developmental screening instruments identify roughly 8% of children as showing developmental
risks in first years of life. In this capacity, our tool will ultimately be designed as a practical, feasible, and
reimbursable health-screening module for wide-scale use in community pediatric settings.

## Key facts

- **NIH application ID:** 10016847
- **Project number:** 5R44MH115528-03
- **Recipient organization:** ADAPTIVE TECHNOLOGY CONSULTING, LLC
- **Principal Investigator:** Joshua W Wade
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $484,987
- **Award type:** 5
- **Project period:** 2018-08-23 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10016847

## Citation

> US National Institutes of Health, RePORTER application 10016847, Autoscreen: An innovative e-health solution for early identification of Autism Spectrum Disorder Phase II (5R44MH115528-03). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10016847. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*